Dietary exposure exceeds the threshold linked to adverse effects in children
EFSA's 2017 re-evaluation found that children eating moderate to high amounts of processed food already take in more added glutamate than the dose associated with the MSG symptom complex, which includes headaches and short-term blood pressure rises in sensitive individuals. When naturally occurring glutamate from food is added on top, the group ADI is exceeded across all age groups. EFSA recommended that maximum permitted levels be cut in several food categories.
Mean dietary exposure to added glutamates in toddlers and children exceeded the dose associated with the MSG symptom complex in human studies; high-level (95th percentile) exposure in infants, toddlers, children, and adolescents surpassed doses linked to headaches and blood pressure increases.
2017Regulatory reviewEFSA Panel on Food Additives and Nutrient Sources added to Food (ANS), re-evaluation of glutamic acid and glutamates E620-E625, EFSA Journal
When naturally occurring glutamate from food is included alongside additive sources, the group ADI of 30 mg/kg body weight per day is largely exceeded for all population groups.
2017Regulatory reviewEFSA ANS Panel re-evaluation of glutamic acid and glutamates E620-E625, EFSA Journal
Neurological effects at high doses in animal studies
A developmental neurotoxicity study in animals identified adverse effects on behaviour in offspring exposed to high doses, including delayed swimming development and altered learning responses. EFSA used this study to set the group ADI for E620-E625, applying a 100-fold uncertainty factor to the no-observed-adverse-effect level. The panel found no concern for genotoxicity or carcinogenicity.
A developmental neurotoxicity study identified adverse neurobehavioural effects in offspring including delayed swimming development, diminished rearing frequency, and altered learning responses at high doses of MSG.
2017AnimalEFSA ANS Panel re-evaluation of glutamic acid and glutamates E620-E625, EFSA Journal
No indication of carcinogenicity was found in chronic studies, and glutamates did not raise concern for genotoxicity.
2017Regulatory reviewEFSA ANS Panel re-evaluation of glutamic acid and glutamates E620-E625, EFSA Journal
German BfR assessment: glutamates and neurological sensitivity
The German Federal Institute for Risk Assessment reviewed the health effects of glutamic acid and its salts used as food additives. It acknowledged reports of the MSG symptom complex in sensitive individuals but noted the evidence base for a clear dose-response relationship in the general population from food exposure remained limited. Both the BfR and EFSA concluded that the human data were not suitable for deriving a formal ADI and relied on animal data instead.
Human data on MSG sensitivity were deemed unsuitable for deriving safety values because they lacked adequate dose-response information; the ADI was therefore derived from animal studies with a full uncertainty factor applied.
RegulatoryBfR (Bundesinstitut fuer Risikobewertung), Assessment of health effects of glutamic acid and glutamates through use as food additives